

April 20, 2017



## Abeona to Present At Multiple Upcoming Conferences

NEW YORK and CLEVELAND, April 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced President and CEO, Timothy J. Miller, PhD, will present at the Gene Therapy for Rare Disorders 2017 and the Alliance of Regenerative Medicine (ARM) 5<sup>th</sup> Annual Cell and Gene Therapy Investor Day, both in Boston, MA.

Below are the specifics of each presentation:

Event: Gene Therapy for Rare Disorders 2017

Date: Wednesday, April 26<sup>th</sup>

Time: 2:30 pm ET

Location: Boston, MA

Website: <http://genetherapy-conference.com/>

Event: Alliance of Regenerative Medicine (ARM) 5<sup>th</sup> Annual Cell & Gene Therapy Investor Day

Date: Thursday, April 27<sup>th</sup>

Time: 4:00 pm ET

Room Name: The Great Room

Location: Boston, MA

Website: <http://arminvestorday.com/>

Webcast: <http://arminvestorday.com/webcast/>

**About Abeona:** Abeona Therapeutics Inc. is a leading clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively). Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit [www.abeonatherapeutics.com](http://www.abeonatherapeutics.com).

*This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and*

*uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.*

**Investor Contact:**

Christine Silverstein  
Vice President, Investor Relations  
Abeona Therapeutics Inc.  
+1 (212)-786-6212  
[csilverstein@abeonatherapeutics.com](mailto:csilverstein@abeonatherapeutics.com)

**Media Contact:**

Andre'a Lucca  
Vice President, Communications & Operations  
Abeona Therapeutics Inc.  
+1 (212)-786-6208  
[alucca@abeonatherapeutics.com](mailto:alucca@abeonatherapeutics.com)



Source: Abeona Therapeutics Inc